CellCept

Company
Roche

Approval Status
Approved February 1998

Treatment for
prevention of organ rejection inpatients undergoing heart transplants

Areas
Cardiovascular / Cardiology , Diabetes / Endocrinology , Immune System

CellCept when used in combination with cyclosporine and corticosteroids has been approved for the prevention of organ rejection inpatients undergoing heart transplants. CellCept has previously been approved for the prevention of organ rejection in kidney-transplant patients.

The principal adverse reactions associated with the administration of Cell Cept include diarrhea, leukopenia (reduction of white blood cells), sepsis, and vomiting, and there is evidence of a higher frequency of certain types of infections.

Cellcept Drug Information

The Cellcept drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top